As Technologies for Nucleotide Therapeutics Mature, Products Emerge

The long path from initial research on oligonucleotide therapies to approval of antisense products is not unfamiliar. This lag resembles those encountered with monoclonal antibodies, gene therapies, and many biological targets and is consistent with studies of innovation showing that technology matu...

Descripción completa

Detalles Bibliográficos
Autores principales: Beierlein, Jennifer M., McNamee, Laura M., Ledley, Fred D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5686430/
https://www.ncbi.nlm.nih.gov/pubmed/29246316
http://dx.doi.org/10.1016/j.omtn.2017.10.017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5686430/
https://www.ncbi.nlm.nih.gov/pubmed/29246316
http://dx.doi.org/10.1016/j.omtn.2017.10.017

Ejemplares similares